To develop medicines for emerging markets
GlaxoSmithKline (GSK) has signed a five-year agreement with the Institute of Chemical and Engineering Sciences (ICES) at the Agency for Science, Technology and Research (A*STAR) in Singapore to develop new evidence based formulations (EBFs) for emerging markets. EBFs are medicines that are reformulated to provide additional patient benefit.
ICES has had a relationship with GSK since 2003. The new collaboration will combine ICES’ expertise in synthesis, formulation and process development with GSK’s drug candidate selection, optimisation and product development in novel formulations.
ICES says the collaboration will enhance its technical expertise in drug product formulation, analytical techniques, development and scale up. It will develop a pool of local expertise in specialised formulation for pharmaceutical development in Singapore.
‘This agreement with ICES is perfectly aligned with GSK’s strategic priority of growing a diversified global business, whilst bringing affordable, quality GSK medicines of value to more people who need them. Within GSK’s portfolio of off-patent products, EBFs are an important part of our growth strategy, and our hope is that together with ICES we will create a sustainable, scalable model to meet both specific market conditions and patient requirements,’ said Duncan McKay, Vice President, Emerging Markets & Asia Pacific R&D at GSK.